Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report
Arakawa, S.; Horiguchi, A.; Tomishige, H.; Kawabe, N.; Nagata, H.; Ishihara, S.; Ito, M.; Asano, Y.; Ito, R.; Isetani, M.; Shimizu, K.; Kamio, K.; Kawai, T.; Yasuoka, H.; Imaeda, Y.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(4): 649-651
2018
ISSN/ISBN: 0385-0684 PMID: 29650823 Document Number: 695766
Chemotherapywith TAS-102 with bevacizumab(Bmab)is a new treatment for metastatic colorectal cancer. A 67-year-old male patient with synchronous multiple liver metastases was treated with TAS-102 with Bmab as a fifth-line chemotherapy. It was demonstrated that liver metastases decreased in size by1 3%bycomputed tomography(CT)after 3 months of TAS-102 with Bmab therapy. The Grade 3 or worst adverse event that was experienced was neutropenia. The patient was able to continue treatment with TAS-102 with Bmab for 6 months. TAS-102 with Bmab treatment was safetyand efficacious as a late-line chemotherapytreatment for metastatic colorectal cancer.